Antibody to signal recognition particle in polymyositis

Targoff, Ira N.; Johnson, Arthur E.; Miller, Frederick W.

doi:10.1002/art.1780330908

Cited by 290 publications

(197 citation statements)

References 54 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…These observations are consistent with an earlier report in which anti-SRP was associated with severe PM and a reduced frequency of interstitial lung disease and arthritis, as compared with anti-aminoacyl-tRNA synthetase antibodies (21). These results suggest that anti-SRP may be a marker for a specific clinical subset of patients who have particularly refractory inflammatory muscle disease.…”

Section: Discussionsupporting

confidence: 92%

Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in japanese patients with inflammatory muscle disease

Hirakata¹,

Mimori²,

Akizuki³

et al. 1992

Arthritis & Rheumatism

123

View full text Add to dashboard Cite

Objective. To elucidate the profile and clinical significance of autoantibodies to small nuclear and small cytoplasmic ribonucleoproteins in Japanese patients with polymyositis and dermatomyositis (PMBM).Methods. Radioimmunoprecipitation assays were performed with sera from 91 patients with various inflammatory muscle diseases and from 254 control patients with other rheumatic diseases. Patients with PWDM were categorized according to autoantibody specificities, and clinical comparisons were made.Results. Antibodies to aminoacyl transfer RNA (tRNA) synthetases and the signal recognition particle (SRP) were found to be specific for PM/DM. PWDM

show abstract

Section: Discussionsupporting

confidence: 92%

Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in japanese patients with inflammatory muscle disease

Hirakata¹,

Mimori²,

Akizuki³

et al. 1992

Arthritis & Rheumatism

123

View full text Add to dashboard Cite

show abstract

“…Currently, the detection of anti-SRP autoantibodies is based on an indirect immunofluorescence test on HEp-2 cells, which typically shows a cytoplasmic pattern (1). Since this profile is not specific, the diagnosis has to be confirmed by an immunodot assay or by protein immunoprecipitation.…”

mentioning

confidence: 99%

Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy

Benveniste

Drouot

Jouen

et al. 2011

Arthritis & Rheumatism

189

132

View full text Add to dashboard Cite

Objective. Anti-signal recognition particle (anti-SRP) autoantibodies are associated with severe acquired necrotizing myopathies. The role of these autoantibodies remains elusive, and the evolution of anti-SRP levels over time is unknown. In this study, we developed an addressable laser bead immunoassay (ALBIA) technique to investigate a correlation between anti-SRP levels, serum creatine kinase (CK) levels, and muscle strength in patients with necrotizing myopathy.Methods. The diagnostic value of the ALBIA assay was determined by comparing serum levels of anti-SRP autoantibodies in 31 anti-SRP immunodotpositive patients to those in 190 healthy blood donors and 199 control patients with different inflammatory/ autoimmune conditions or polyclonal hypergammaglobulinemia. Among the 31 anti-SRP-positive patients, serum samples from 8 patients were monitored over time for levels of anti-SRP autoantibodies and levels of CK (determined at least 3 times, consecutively, over a mean followup period of 783 days). The relationship between levels of anti-SRP autoantibodies and levels of CK was tested using a linear mixed model.Results. The assay yielded positive results for anti-SRP in all anti-SRP immunodot-positive serum samples tested, while all control sera tested negative. The 8 anti-SRP-positive patients who were followed up longitudinally were found to have normalized CK levels and improved muscle strength. There was a striking correlation between the degree of myolysis, as measured by CK levels, in patients receiving therapy and the anti-SRP54 autoantibody levels in these same patients (P ‫؍‬ 0.002).Conclusion. Anti-SRP-positive myositis appears to be one of the few autoimmune diseases in which specific autoantibody levels are correlated with surrogate disease activity markers. These results reveal the usefulness of monitoring anti-SRP autoantibody levels in patients receiving therapy, and may also suggest a possible pathogenic role for anti-SRP autoantibodies in the necrotizing myopathies.Autoantibodies directed against signal recognition particles (anti-SRP) are present in a minority (4-6%) of patients with acquired inflammatory and/or necrotizing myopathies (1-5). Anti-SRP autoantibodies are generally associated with severe clinical forms of the disease, particularly those with heart and lung involvement (6,7) and resistance to steroid therapy (8-10).

show abstract

“…16 Thus, the determination of clinical and laboratory signs for association with malignancy are of great importance for the disease prognosis. In some studies, relatively high proportions of anti-155/140 antibodies were detected in cancer-associated DM patients, and these have an excellent positive predictive value 12,13,17 Therefore, introduction of a commercial kit for this antibody to be applied in clinical screening may be beneficial. It was also shown that anti-Jo-1 antibody and cancer-associated DM, or interstitial lung disease and cancerassociated DM appear mutually exclusive.…”

Section: Discussionmentioning

confidence: 99%

“…It was also shown that anti-Jo-1 antibody and cancer-associated DM, or interstitial lung disease and cancerassociated DM appear mutually exclusive. AntiJo-1 antibody and interstitial lung disease are both associated with a specific human leukocyte antigen class II haplotype, and anti-155/140 antibody is associated with human leukocyte antigen-DQA1*0301, 17 suggesting that cancer risk in DM may be genetically determined. Thus DM patients may suffer multiple tumors due to genetic susceptibility.…”

Section: Discussionmentioning

confidence: 99%

Metachronous Basal Cell Carcinoma and Primary Plasmacytic Leukemia Associated With Dermatomyositis

2014

View full text Add to dashboard Cite

Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by the association of progressive proximal muscle weakness and specific cutaneous signs, as well as multisystemic manifestations.1 Although the association between DM and elevated risks of comorbid cancers has been studied extensively, 2 individuals with multiple malignancies associated with DM are rare. Some previous reports associated DM and two different types of malignancies in the same individual. [3][4][5] To the best of our knowledge, this is the first case of the metachronous basal-cell carcinoma of the nasolabial fold and plasma cell leukemia occurring in the same DM patient over a period of time. CASE REPORTA 71-year-old female patient presented with a four-month history of muscle weakness, such as difficulty in raising her hands over the level of her shoulders and walking up and down the stairs. Physical examination revealed periorbital violaceous erythema and Gottron's papules on both elbows. Strength testing demonstrated a grade of 3/5 for the cervical muscle, upper and lower limbs. Laboratory tests showed elevated muscle enzymes with a creatine phosphokinase

show abstract

Antibody to signal recognition particle in polymyositis

Cited by 290 publications

References 54 publications

Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in japanese patients with inflammatory muscle disease

Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in japanese patients with inflammatory muscle disease

Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy

Metachronous Basal Cell Carcinoma and Primary Plasmacytic Leukemia Associated With Dermatomyositis

Contact Info

Product

Resources

About